Webinar

Detecting Arrhythmias in Clinical Trials Using ECG Monitoring

Please join us for this free webinar on trends in event and continuous ECG monitoring, and implications for clinical trials of both medical devices and drug therapies. Presented by Polina Voloshko, MD, Chief Medical Officer, BioTel Research.

Apr 16, 2019 | 1:00 PM

Webinar

Body Composition in Clinical Trials – From BMI to MRI

In this free webinar, BioTel Research’s Vice President of Musculoskeletal and Metabolic Imaging, Jonathan Riek, PhD, and AMRA’s Chief Scientific Officer & Co-Founder, Olof Dahlqvist Leinhard, PhD, present alternative, noninvasive imaging methods to determine body composition.

Feb 13, 2018 | 11:00 AM

Webinar

Key Takeaways from the New CSRC/FDA Meeting on Cardiac Safety and Cardiovascular Safety Issues in Oncology Drug Development

In this free webinar, Polina Voloshko, MD, Chief Medical Officer and Daniel Goodman, MD, Vice President and Medical Director, present the updates from the 2017 CSRC/FDA meeting on cardiac safety and cardiovascular safety issues in oncology drug development to optimize your clinical trial.

Nov 1, 2017 | 11:00 AM

Webinar

Optimize the Imaging in Clinical Trials by Aligning Operational Excellence and Scientific Expertise

In this free webinar, Ed Ashton, PhD, Vice President of Oncology Imaging and Danielle Lewis, MS, PMP, Global Operations Account Manager, present real-world scientific and operational examples of errors that can occur during your imaging clinical trial and how you can prevent them.

Sep 13, 2017 | 11:00 AM

Webinar

Assessing NASH: Discover the Non-invasive Techniques

In this free webinar, Richard Ehman, MD from the Mayo Clinic and BioTel Research’s Jonathan Riek, PhD, VP, Musculoskeletal and Metabolic Imaging discuss non-invasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, magnetic resonance elastography (MRE), and the latest advances in MRE.

Apr 13, 2017 | 11:00 AM

White Paper

Exploring Immunotherapies: Beyond Checkpoint Inhibitors

Immunotherapy is an emerging class of cancer treatment, which stimulates the body’s immune system to fight cancer. With the approval of three checkpoint inhibitors (ipilimumab, pembrolizumab and nivolumab) by the FDA in the past five years, immunotherapies are seen as exciting treatments able to elicit durable cures. Download our white paper to discover: Emerging immunotherapeutic […]

Jun 1, 2016